Mdm2, an oncoprotein that regulates the tumor suppressor p53, and Myc, an oncoprotein that paradoxically drives both cell cycle progression and apoptosis, are overexpressed in many human malignancies. We have demonstrated in vivo that Mdm2 overexpression was frequently selected for during Myc-induced B cell lymphoma development in E?-myc transgenic mice, a murine model of human non-Hodgkin's lymphoma where Myc is overexpressed specifically in B cells. Surprisingly, Mdm2 overexpression frequently occurred in lymphomas that had inactivated p53 or p19ARF, a regulator of Mdm2. These observations suggest that Mdm2 plays a role in lymphomagenesis, and that Mdm2 may function independent of both tumor suppressors p53 and ARF during lymphoma development. We will test these hypotheses with in vivo approaches utilizing mouse tumor models and in vitro primary pre-B cell and tumor cell analyses. Experiments in Aim #1 will determine, in a genetic fashion, the impact of Mdm2 overexpression on B cell development and transformation and the extent to which Mdm2 synergizes with Myc during lymphoma development. Experiments in Aim #2 will evaluate the influence Mdm2 expression has on Myc-induced apoptosis and whether Mdm2 is required for Myc-induced lymphomagenesis. Experiments in Aim #3 will identify and characterize novel targets of Mdm2 and p53/ARF-independent pathways that mediate Mdm2's oncogenic properties. Together these studies will elucidate the role(s) Mdm2 has in lymphoma development and provide much needed insight on the mechanisms involved in B cell transformation. Results from these investigations should ultimately lead to improved intervention strategies for the treatment of human non-Hodgkin's lymphoma. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098139-02
Application #
6770198
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Mufson, R Allan
Project Start
2003-07-01
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
2
Fiscal Year
2004
Total Cost
$314,769
Indirect Cost
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Arrate, Maria Pia; Vincent, Tiffaney; Odvody, Jessica et al. (2010) MicroRNA biogenesis is required for Myc-induced B-cell lymphoma development and survival. Cancer Res 70:6083-92
Odvody, J; Vincent, T; Arrate, M P et al. (2010) A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene 29:3287-96
Bouska, Alyssa; Eischen, Christine M (2009) Mdm2 affects genome stability independent of p53. Cancer Res 69:1697-701
Bouska, Alyssa; Eischen, Christine M (2009) Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci 34:279-86
Bouska, Alyssa; Lushnikova, Tamara; Plaza, Silvia et al. (2008) Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 28:4862-74
Iwakuma, T; Tochigi, Y; Van Pelt, C S et al. (2008) Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene 27:1813-20
Wang, P; Lushnikova, T; Odvody, J et al. (2008) Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 27:1590-8
Tompkins, Van S; Hagen, Jussara; Frazier, April A et al. (2007) A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J Biol Chem 282:1322-33
Wang, P; Greiner, T C; Lushnikova, T et al. (2006) Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene 25:3708-18
Eischen, Christine M; Alt, Jodi R; Wang, Peng (2004) Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Oncogene 23:8931-40